203 related articles for article (PubMed ID: 17075781)
1. Biguanides enhance glucose utilization and insulin action in peripheral tissues: an old finding from the sixties of the last century.
Schatz H
Horm Metab Res; 2006 Oct; 38(10):690. PubMed ID: 17075781
[No Abstract] [Full Text] [Related]
2. [Pharmacologic treatment of diabetes].
De Montigny P; Clerc C; Descarpentries C
Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
[No Abstract] [Full Text] [Related]
3. [Oral antidiabetic agents including glucosidase inhibitors].
Raptis S
Internist (Berl); 1987 Apr; 28(4):243-53. PubMed ID: 3298124
[No Abstract] [Full Text] [Related]
4. [Results in diabetic therapy with Silubin retard. 3].
Kopp H
Med Klin; 1971 Feb; 66(7):246-7. PubMed ID: 5552720
[No Abstract] [Full Text] [Related]
5. [Application of the method of continuois recording of glycemia to the study of the action of hypoglycemic agents in the diabetic].
Drouin P; Mejean L; Guisard D; Debry G
Nutr Metab; 1974; 16(5):261-7. PubMed ID: 4836869
[No Abstract] [Full Text] [Related]
6. [On the clinical use of biguanides].
Haese E
Arzneimittelforschung; 1969 Apr; 19(4):633-8. PubMed ID: 5819164
[No Abstract] [Full Text] [Related]
7. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
8. [Oral treatment of diabetes mellitus with the new sulfonylurea tolazamide].
Vogel G; Krummel E
Arzneimittelforschung; 1969 Jul; 19(7):1128-30. PubMed ID: 5394514
[No Abstract] [Full Text] [Related]
9. Type II diabetes: insulin versus oral agents.
Martin DB
N Engl J Med; 1986 May; 314(20):1314-5. PubMed ID: 3517646
[No Abstract] [Full Text] [Related]
10. [Intensification of insulin therapy in type 2 diabetics].
Davidson JA
Journ Annu Diabetol Hotel Dieu; 2007; ():85-8. PubMed ID: 18610760
[No Abstract] [Full Text] [Related]
11. Treatment options for type 2 diabetes. Finding what's best for you.
Clark W
Diabetes Self Manag; 2002; 19(3):6-10, 13. PubMed ID: 12091971
[No Abstract] [Full Text] [Related]
12. [Clinical difference between thiazolidinediones and biguanides].
Hotta N
Nihon Rinsho; 2001 Nov; 59(11):2219-27. PubMed ID: 11712411
[TBL] [Abstract][Full Text] [Related]
13. [Oral antidiabetic agents for the general practitioner].
Siegmund T
MMW Fortschr Med; 2009 Apr; 151(14):86, 88-91; quiz 92. PubMed ID: 19504847
[No Abstract] [Full Text] [Related]
14. A 48-year-old man with uncontrolled diabetes.
Hu M; Isaacson JH
Cleve Clin J Med; 2009 Jul; 76(7):413-6. PubMed ID: 19570974
[No Abstract] [Full Text] [Related]
15. [Current status of diet and drug therapy of diabetes mellitus in children].
Dumitrescu C; Vasilescu V
Pediatria (Bucur); 1968; 17(4):317-21. PubMed ID: 5701382
[No Abstract] [Full Text] [Related]
16. Clinical experience with glynclamide, a new hypoglycaemic agent.
Burns FH
Med J Aust; 1969 Aug; 2(9):436-9. PubMed ID: 4898056
[No Abstract] [Full Text] [Related]
17. Biguanides and NIDDM.
Bailey CJ
Diabetes Care; 1992 Jun; 15(6):755-72. PubMed ID: 1600835
[TBL] [Abstract][Full Text] [Related]
18. [Biguanides in oral antidiabetic therapy: indications and limitations].
Gregorio F; Filipponi P
Medicina (Firenze); 1988; 8(3):262-8. PubMed ID: 3231038
[No Abstract] [Full Text] [Related]
19. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
20. [Results of diabetes therapy with Silubin retard].
Kopp H
Med Klin; 1966 Apr; 61(15):592-6. PubMed ID: 4869026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
